
|Videos|January 31, 2021
Glaukos COO shares product updates, 2021 pipeline
Author(s)David Hutton, Alex Delaney-Gesing
Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
2
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081
3
Ocular Therapeutix randomizes first patient in HELIOS-3
4
AAO 2025 Takeaways: How imaging and remote monitoring are transforming retinal care
5


















































.png)


